Impact Report 2020
The WFH Humanitarian Aid Program was developed to address the issue of access to care by working with WFH NMOs to provide continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and prophylaxis for young children. In 2020, the program quickly responded to the COVID-19 pandemic by bringing education online and by collaborating with local organizations facing logistical restrictions in order to ensure that care would not be interrupted. 2020 also saw the WFH deliver the very first shipments of emicizumab to patients—a new prophylactic treatment to reduce the frequency of bleeding episodes in adults and children of all ages, newborn and older, with hemophilia A, with and without factor VIII inhibitors.